150 related articles for article (PubMed ID: 38155625)
21. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
22. A surveillance conundrum: a case of 4 distinct primary malignancies in a BRCA-1 mutation carrier.
Ricci S; Shafer A; Nerenstone S; Mandavilli S; Sorosky J
Int J Gynecol Pathol; 2012 Mar; 31(2):145-8. PubMed ID: 22317870
[TBL] [Abstract][Full Text] [Related]
23. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
25. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages].
Canlorbe G; Lecointre L; Chauvet P; Azaïs H; Fauvet R; Uzan C
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):287-303. PubMed ID: 32004786
[TBL] [Abstract][Full Text] [Related]
26. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA
Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
[TBL] [Abstract][Full Text] [Related]
27. Management of hereditary breast and ovarian cancer.
Yamauchi H; Takei J
Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
[TBL] [Abstract][Full Text] [Related]
28. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
29. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
30. Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer.
Quan ML; Fey J; Eitan R; Abu-Rustum NR; Barakat RR; Borgen PI; Gemignani ML
Gynecol Oncol; 2004 Jan; 92(1):327-30. PubMed ID: 14751178
[TBL] [Abstract][Full Text] [Related]
31. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
33. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
34. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
35. Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
George SHL; Donenberg T; Alexis C; DeGennaro V; Dyer H; Yin S; Ali J; Butler R; Chin SN; Curling D; Lowe D; Lunn J; Turnquest T; Wharfe G; Cerbon D; Barreto-Coelho P; Schlumbrecht MP; Akbari MR; Narod SA; Hurley JE
JAMA Netw Open; 2021 Mar; 4(3):e210307. PubMed ID: 33646313
[TBL] [Abstract][Full Text] [Related]
36. [Hereditary breast and ovarian cancer].
Lax SF
Pathologe; 2017 May; 38(3):149-155. PubMed ID: 28500412
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
38. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
[TBL] [Abstract][Full Text] [Related]
39. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.
Casey MJ; Bewtra C; Lynch HT; Snyder CL; Stacey M
Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400
[TBL] [Abstract][Full Text] [Related]
40. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
